Abstract:Objective To analyze the influence of recombinant human brain natriuretic peptide (rh- BNP) preconditioning combined percutanous coronary intervention (PCI) therapy on AMI patients’ cardiac function. Methods Seventy-eight patients with AMI were included in the study, and divided into an observation group and a control group according to the random number table method, each with 39 patients. The patients of the control group received conventional PCI treatment, and the patients in the observation group received rh-BNP preconditioning combined PCI treatment. The changes in the values of ventricular remodeling indexes, cardiac function and serum related indexes were compared between the two groups. Results The values of left ventricular end diastolic diameter (LVDd), interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular mass index (LVMI), left ventricular end systolic volume (LVESV), and left ventricular end diastolic volume (LVEDV) in the observation group were lower than those in the control group; the values of left ventricular ejection fraction (LVEF), and mitral valve early diastolic blood flow rate (VE)/atrial systolic flow velocity (VA) were higher than those of the control group (P < 0.05); the values of serum N-terminal-pro-B-type natriuretic peptide, type Ⅲ procollagen, and heart fatty acid binding protein were lower than those of the control group (P < 0.05). Conclusions rh-BNP preconditioning combined PCI therapy can enhance the cardiac function of AMI patients, and optimize the long-term treatment outcomes.